Upon final approval, Teva's sumatriptan succinate tablets will be the AB-rated generic equivalent of GlaxoSmithKline's Imitrex tablets. Final approval is expected upon expiry of patent protection for the brand product in February 2009.
The brand product had annual sales of approximately $910 million for the twelve months ended September 2006, based on IMS sales data.
Teva Pharmaceutical Industries is headquartered in Israel and develops, manufactures and markets generic and human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products.